
Interim advice for healthcare professionals
MHRA issues updated monitoring advice for givinostat
The Medicines and Healthcare products Regulatory Agency (MHRA) has published interim advice for healthcare professionals on additional risk minimisation measures for people taking givinostat (Duvyzat).
We are sharing a statement from Duchenne Care UK and the NorthStar Network about the guidance, and summary from NHS England.
Message to the patient community from Duchenne Care UK and NorthStar in response to MHRA interim advice on risk mitigation for givinostat
On 5 November 2026, the MHRA issued an interim update to safety advice for givinostat in response to a small number of deaths previously reported outside the UK in patients who were taking the medication.
You might remember that a statement was issued by NorthStar and Duchenne Care UK to the Duchenne community on 22 October 2025 regarding these deaths; and that at that time the MHRA was asked for advice.
To our knowledge, the MHRA statement on 5 November 2026 relates to the deaths reported in October 2025 and we are unaware of any additional unexplained deaths or new safety concerns in people taking givinostat since that time.
Duchenne Care UK and NorthStar are asking the MHRA for clarification on some of the wording used in their interim update, particularly around the additional ECG heart monitoring in patients starting givinostat and whether patients already taking givinostat need further assessments.
It is our understanding that MHRA has no new evidence suggesting that the deaths were a direct result of givinostat use. However, as previously explained, it is also not possible to definitively rule out a potential contribution of givinostat in these cases. More research is needed to better understand the safety of givinostat now that it is being prescribed to a wider group of people with DMD, and we are working together in the clinical networks to identify the best way to answer these important questions.
Meanwhile, MHRA have endorsed the clinical recommendations from Duchenne Care UK for prescription and monitoring of givinostat which they advise should still be followed in the UK.
If you have any concerns or questions, please do discuss these with your clinical team. We will update the community as soon as we have any additional information.
Givinostat (Duvyzat®): information for patients from NHS England
The UK medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), has issued interim safety advice about givinostat, also known by the brand name Duvyzat®. Givinostat is a treatment for some people aged 6 years and over with Duchenne muscular dystrophy (DMD).
A small number of deaths have been reported outside the UK in people with DMD who were taking givinostat. No deaths have been reported in the UK. The MHRA has reviewed the available information and has proposed changes to the monitoring requirements for people taking the medicine. An independent review is now taking place. The MHRA will consider the review before any changes to the product information are finalised.
If you are taking givinostat, continue taking it as prescribed. Attend all your appointments and monitoring, and tell your specialist team about all other medicines you take and any changes to them.
The interim advice includes additional monitoring. Your specialist team will explain which checks you need and when. If you are worried or have questions about your treatment, contact your specialist Duchenne team.
The most important things to do now:
- Keep taking givinostat as prescribed
- Attend all appointments and monitoring
- Tell your specialist team about every medicine you take and any changes to those medicines
- Contact your specialist Duchenne team if you have concerns.
Q and A
What has happened?
The MHRA has issued interim advice about the monitoring of people taking givinostat. This is because there have been reports of a small number of deaths, outside the UK, in people with Duchenne Muscular Dystrophy (DMD) who were taking the medicine. The MHRA has reviewed the available information, and an independent review is now taking place before it finalises its position.
Have any deaths been reported in the UK?
No. The MHRA says that no deaths have been reported in the UK.
Should I keep taking givinostat?
Yes. Continue taking givinostat as prescribed. Speak to your specialist Duchenne team before making any changes to your treatment.
Do I need to contact my specialist team now?
Continue to attend your appointments and monitoring. If you have questions or concerns about your treatment, speak to your specialist Duchenne team. Your team will let you know about any additional monitoring you need.
What additional monitoring is being advised?
The additional monitoring includes ECGs and blood tests. The checks you need, and when you need them, will depend on where you are in your treatment. Your specialist team will explain what this means for you.
Why do I need additional monitoring?
The additional monitoring is intended to help make sure that givinostat remains as safe as possible for people with Duchenne muscular dystrophy. Your specialist team will arrange the checks you need and explain what they mean for you.
What should I tell my specialist team about other medicines?
Make sure your specialist team knows about all the medicines you take, including medicines or supplements you buy yourself. Tell your specialist team if anything changes.
What if I am due to start givinostat?
Your specialist team will consider whether givinostat is suitable for you and arrange the monitoring you need before and after you start treatment. Make sure the team knows about your health conditions and all the medicines you take.
Will the advice be updated?
Yes. This is interim advice while an independent review takes place. The MHRA will consider the findings of that review before finalising any changes to the product information. It will publish a further Drug Safety Update to communicate any finalised changes.
What does the black triangle symbol mean?
The black triangle symbol (▼) means that givinostat is a medicine that is subject to additional monitoring. Healthcare professionals, patients and carers are asked to report all suspected side effects through the MHRA Yellow Card scheme. This helps the MHRA collect information about the medicine's safety.
How can I report a suspected side effect?
Patients, parents and carers can report suspected side effects through the MHRA Yellow Card scheme. When making a report, provide as much information as you can, including what happened, when it started, treatment dates, medical history and any other medicines being taken.
Where can I get more help or information?
If you have questions or concerns about your treatment, speak to your specialist Duchenne team.
Useful links



